Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Regenxbio Inc (RGNX)
Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 765,901
  • Shares Outstanding, K 43,992
  • Annual Sales, $ 112,720 K
  • Annual Income, $ -280,320 K
  • 60-Month Beta 1.20
  • Price/Sales 7.63
  • Price/Cash Flow N/A
  • Price/Book 2.20
Trade RGNX with:

Options Overview Details

View History
  • Implied Volatility 72.60% ( -5.80%)
  • Historical Volatility 79.01%
  • IV Percentile 59%
  • IV Rank 32.35%
  • IV High 118.28% on 02/02/24
  • IV Low 50.77% on 11/17/23
  • Put/Call Vol Ratio 0.80
  • Today's Volume 18
  • Volume Avg (30-Day) 99
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 2,098
  • Open Int (30-Day) 1,736

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.13
  • Number of Estimates 5
  • High Estimate -0.58
  • Low Estimate -1.38
  • Prior Year -1.38
  • Growth Rate Est. (year over year) +18.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.83 +55.37%
on 02/02/24
20.34 -9.64%
on 02/16/24
+5.66 (+44.50%)
since 01/26/24
3-Month
11.83 +55.37%
on 02/02/24
21.38 -14.03%
on 12/14/23
-1.12 (-5.74%)
since 11/24/23
52-Week
11.83 +55.37%
on 02/02/24
25.32 -27.41%
on 03/01/23
-2.93 (-13.75%)
since 02/24/23

Most Recent Stories

More News
Regenxbio: Q3 Earnings Snapshot

Regenxbio: Q3 Earnings Snapshot

RGNX : 18.29 (+5.05%)
REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023. Jefferies...

RGNX : 18.29 (+5.05%)
REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be...

RGNX : 18.29 (+5.05%)
REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in...

RGNX : 18.29 (+5.05%)
REGENXBIO to Participate in Upcoming Investor Conferences

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual...

RGNX : 18.29 (+5.05%)
Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that initial interim data from a first-in-human single-patient, investigator-initiated trial of...

RGNX : 18.29 (+5.05%)
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023...

RGNX : 18.29 (+5.05%)
Regenxbio: Q2 Earnings Snapshot

Regenxbio: Q2 Earnings Snapshot

RGNX : 18.29 (+5.05%)
REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights

Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or...

RGNX : 18.29 (+5.05%)
REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference...

RGNX : 18.29 (+5.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 19.40
2nd Resistance Point 18.92
1st Resistance Point 18.16
Last Price 18.29
1st Support Level 16.92
2nd Support Level 16.44
3rd Support Level 15.68

See More

52-Week High 25.32
Fibonacci 61.8% 20.17
Fibonacci 50% 18.58
Last Price 18.29
Fibonacci 38.2% 16.98
52-Week Low 11.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar